Search the Community
Showing results for tags 'pde-5 inhibitors'.
Found 1 result
Complex pathophysiology of pulmonary hypertension (PAH) associated with systemic sclerosis (SSc): potential unfavorable effects of vasodilators. Pre–assessment of pathophysiology of pulmonary hypertension and cautious monitoring during the treatment are necessary to achieve better outcomes in patients with SSc–PAH. Journal of Scleroderma and Related Disorders, JSRD 2017; 2(2): 92 - 99. (Also see Treatments for Pulmonary Arterial Hypertension: PDE-5 Inhibitors) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.